Compare Baidu Inc (BIDU) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baidu Inc vs Incyte Corporation — how do they compare? Baidu Inc trades at $104.84 (market cap $36.18B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Baidu Inc is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| BIDU | INCY | |
|---|---|---|
Market Cap | $36.18B | $24.54B |
Sector | Media | Health |
52-Week High | $162.52 | $129.93 |
52-Week Low | $86.76 | $81.61 |
Enterprise Value | $32.81B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baidu (BIDU) trades at $104.41, down 4.65% today amid broader pressure on Chinese stocks. The stock shows a bearish technical signal, with recent earnings missing expectations in Q1 2026. Revenue declined to $129.08B in 2025, and net income margin compressed to 1.02%. However, analyst consensus remains strongly bullish with a $169.80 price target, and the company is advancing AI initiatives, including autonomous vehicle testing in London.
The outlook is mixed: strong analyst support and AI growth potential offer upside, but weak profitability, declining revenue, and macroeconomic risks in China pose significant challenges. Investors should weigh the high P/E of 78.19 against future AI-driven earnings acceleration.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
